BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM. Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep. 2015;5:18559. [PMID: 26692421 DOI: 10.1038/srep18559] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018;44:34-40. [PMID: 30036705 DOI: 10.1016/j.mib.2018.07.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 26.3] [Reference Citation Analysis]
3 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
4 Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep. 2016;6:26800. [PMID: 27225869 DOI: 10.1038/srep26800] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
5 Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
6 Cui B, Guo G, Hui Y, Wang X, Liu W, Sun C. The prognostic value of high-density lipoprotein cholesterol in patients with decompensated cirrhosis: a propensity score matching analysis. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.03.009] [Reference Citation Analysis]
7 Bajaj JS, Fagan A, White MB, Wade JB, Hylemon PB, Heuman DM, Fuchs M, John BV, Acharya C, Sikaroodi M, Gillevet PM. Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. Am J Gastroenterol. 2019;. [PMID: 30816877 DOI: 10.14309/ajg.0000000000000102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
8 Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM. Fungal dysbiosis in cirrhosis. Gut 2018;67:1146-54. [DOI: 10.1136/gutjnl-2016-313170] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
9 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol 2021;9:748253. [PMID: 34900994 DOI: 10.3389/fcell.2021.748253] [Reference Citation Analysis]
11 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
12 Tessier MEM, Cavallo L, Yeh J, Harpavat S, Hoffman KL, Petrosino JF, Shneider BL. The Fecal Microbiome in Infants With Biliary Atresia Associates With Bile Flow After Kasai Portoenterostomy. J Pediatr Gastroenterol Nutr 2020;70:789-95. [PMID: 32443032 DOI: 10.1097/MPG.0000000000002686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2:e94416. [PMID: 28978799 DOI: 10.1172/jci.insight.94416] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 14.4] [Reference Citation Analysis]
14 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
15 Saunders JM, Moreno JL, Ibi D, Sikaroodi M, Kang DJ, Muñoz-Moreno R, Dalmet SS, García-Sastre A, Gillevet PM, Dozmorov MG, Bajaj JS, González-Maeso J. Gut microbiota manipulation during the prepubertal period shapes behavioral abnormalities in a mouse neurodevelopmental disorder model. Sci Rep 2020;10:4697. [PMID: 32170216 DOI: 10.1038/s41598-020-61635-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
16 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Tana C, Ventura M, Meschi T. Gut Microbiome in the Elderly Hospitalized Patient. Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications. Elsevier; 2019. pp. 287-96. [DOI: 10.1016/b978-0-12-815249-2.00030-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sivaraj S, Chan A, Pasini E, Chen E, Lawendy B, Verna E, Watt K, Bhat M. Enteric dysbiosis in liver and kidney transplant recipients: a systematic review. Transpl Int 2020;33:1163-76. [PMID: 32640109 DOI: 10.1111/tri.13696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bajaj JS, Torre A, Rojas ML, Fagan A, Nandez IE, Gavis EA, De Leon Osorio O, White MB, Fuchs M, Sikaroodi M, Gillevet PM. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. Liver Int 2020;40:1395-407. [PMID: 32181561 DOI: 10.1111/liv.14437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Cassard AM, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol 2018;24:100-7. [PMID: 29268595 DOI: 10.3350/cmh.2017.0067] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
20 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Ventura M, Meschi T. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 2017;7:11102. [PMID: 28894183 DOI: 10.1038/s41598-017-10734-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 16.6] [Reference Citation Analysis]
21 Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019;70:1690-1703. [PMID: 31038755 DOI: 10.1002/hep.30690] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
22 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 100.3] [Reference Citation Analysis]
23 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
24 Li R, Yang J, Saffari A, Jacobs J, Baek KI, Hough G, Larauche MH, Ma J, Jen N, Moussaoui N, Zhou B, Kang H, Reddy S, Henning SM, Campen MJ, Pisegna J, Li Z, Fogelman AM, Sioutas C, Navab M, Hsiai TK. Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites. Sci Rep 2017;7:42906. [PMID: 28211537 DOI: 10.1038/srep42906] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
25 Bajaj JS, Acharya C, Sikaroodi M, Gillevet PM, Thacker LR. Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. GastroHep 2020;2:79-86. [PMID: 33071650 DOI: 10.1002/ygh2.390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Betrapally NS, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? Gastroenterology 2016;150:1745-1755.e3. [PMID: 26948887 DOI: 10.1053/j.gastro.2016.02.073] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 12.2] [Reference Citation Analysis]
27 Shaw J, Bajaj JS. Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients? Aliment Pharmacol Ther 2017;45:476-7. [PMID: 28043093 DOI: 10.1111/apt.13875] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A, di Nunzio S, Shah A, Giacomelli L, Sacco R. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3401. [PMID: 34943908 DOI: 10.3390/cells10123401] [Reference Citation Analysis]
29 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
30 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Huang R. Gut Microbiota: A Key Regulator in the Effects of Environmental Hazards on Modulates Insulin Resistance. Front Cell Infect Microbiol 2022;11:800432. [DOI: 10.3389/fcimb.2021.800432] [Reference Citation Analysis]
32 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
33 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
34 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
35 Bajaj JS, Fan S, Thacker LR, Fagan A, Gavis E, White MB, Heuman DM, Fuchs M, Fiehn O. Serum and urinary metabolomics and outcomes in cirrhosis. PLoS One 2019;14:e0223061. [PMID: 31560724 DOI: 10.1371/journal.pone.0223061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:107-20. [DOI: 10.1002/hep.30036] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 38.8] [Reference Citation Analysis]
37 He X, Qi Z, Hou H, Gao J, Zhang X. Effects of chronic cadmium exposure at food limitation-relevant levels on energy metabolism in mice. Journal of Hazardous Materials 2020;388:121791. [DOI: 10.1016/j.jhazmat.2019.121791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
38 Bajaj JS. Gut Microbiota as Biosensors in Patients With Cirrhosis. Cell Mol Gastroenterol Hepatol 2019;8:231-3. [PMID: 31132339 DOI: 10.1016/j.jcmgh.2019.04.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
40 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 12.2] [Reference Citation Analysis]
42 Xia GH, You C, Gao XX, Zeng XL, Zhu JJ, Xu KY, Tan CH, Xu RT, Wu QH, Zhou HW, He Y, Yin J. Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke. Front Neurol 2019;10:397. [PMID: 31068891 DOI: 10.3389/fneur.2019.00397] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
43 Lkhagva E, Chung HJ, Hong J, Tang WHW, Lee SI, Hong ST, Lee S. The regional diversity of gut microbiome along the GI tract of male C57BL/6 mice. BMC Microbiol 2021;21:44. [PMID: 33579191 DOI: 10.1186/s12866-021-02099-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
44 Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant 2019;25:827-33. [PMID: 30572109 DOI: 10.1016/j.bbmt.2018.12.069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
45 Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:756-765.e3. [PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
46 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
47 Liu ZJ, Yan YJ, Weng HL, Ding HG. Type 2 diabetes mellitus increases liver transplant-free mortality in patients with cirrhosis: A systematic review and meta-analysis. World J Clin Cases 2021; 9(20): 5514-5525 [PMID: 34307604 DOI: 10.12998/wjcc.v9.i20.5514] [Reference Citation Analysis]
48 Czarnecka K, Czarnecka P, Tronina O, Bączkowska T, Durlik M. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. Immun Inflamm Dis 2021. [PMID: 34598315 DOI: 10.1002/iid3.538] [Reference Citation Analysis]
49 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Liu J, Lkhagva E, Chung HJ, Kim HJ, Hong ST. The Pharmabiotic Approach to Treat Hyperammonemia. Nutrients 2018;10:E140. [PMID: 29382084 DOI: 10.3390/nu10020140] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
51 Bai R, Bai M, Zhao Z, Chen N, Yang Y, Tang Z. Alternation of supragingival microbiome in patients with cirrhosis of different Child-Pugh scores. Oral Dis 2020. [PMID: 33274586 DOI: 10.1111/odi.13743] [Reference Citation Analysis]